Movement Alert｜Johnson & Johnson Rises 3.02% in Regular Trading, Multiple Positive Clinical Readouts Boost Market Confidence

Market Focus06-06 02:39

On June 6, Johnson & Johnson rose 3.02% in regular trading, trading at $235.1/share, with trading volume of $921 million. The rally was driven by a concentrated wave of positive clinical data disclosures across multiple pipeline programs.

Specifically, Nipocalimab met its primary endpoint in a Phase 2 study of moderate-to-severe systemic lupus erythematosus, significantly reducing disease activity at 24 weeks as measured by the SLE Responder Index 4. The drug also demonstrated a 62.5% response rate in autoantibody-high Sjögren's syndrome patients in the Dahlias Phase 2 trial. The safety profile remained consistent with prior studies, with no new safety signals identified. Johnson & Johnson is currently recruiting for a Phase 3 study.

Additionally, late-stage data for Tecvayli showed statistically significant improvements in progression-free and overall survival in advanced multiple myeloma, with nearly two-thirds of patients achieving complete response or better. The FDA also approved a label expansion for Tremfya covering structural joint damage progression in psoriatic arthritis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160653703?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-06 02:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160653703","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Johnson & Johnson Rises 3.02% in Regular Trading, Multiple Positive Clinical Readouts Boost Market Confidence","media":"Market Focus","content":"<p><p>On June 6, Johnson & Johnson rose 3.02% in regular trading, trading at $235.1/share, with trading volume of $921 million. The rally was driven by a concentrated wave of positive clinical data disclosures across multiple pipeline programs.</p><p>Specifically, Nipocalimab met its primary endpoint in a Phase 2 study of moderate-to-severe systemic lupus erythematosus, significantly reducing disease activity at 24 weeks as measured by the SLE Responder Index 4. The drug also demonstrated a 62.5% response rate in autoantibody-high Sjögren's syndrome patients in the Dahlias Phase 2 trial. The safety profile remained consistent with prior studies, with no new safety signals identified. Johnson & Johnson is currently recruiting for a Phase 3 study.</p><p>Additionally, late-stage data for Tecvayli showed statistically significant improvements in progression-free and overall survival in advanced multiple myeloma, with nearly two-thirds of patients achieving complete response or better. The FDA also approved a label expansion for Tremfya covering structural joint damage progression in psoriatic arthritis.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Johnson & Johnson Rises 3.02% in Regular Trading, Multiple Positive Clinical Readouts Boost Market Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Johnson & Johnson Rises 3.02% in Regular Trading, Multiple Positive Clinical Readouts Boost Market Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-06 02:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 6, Johnson & Johnson rose 3.02% in regular trading, trading at $235.1/share, with trading volume of $921 million. The rally was driven by a concentrated wave of positive clinical data disclosures across multiple pipeline programs.</p><p>Specifically, Nipocalimab met its primary endpoint in a Phase 2 study of moderate-to-severe systemic lupus erythematosus, significantly reducing disease activity at 24 weeks as measured by the SLE Responder Index 4. The drug also demonstrated a 62.5% response rate in autoantibody-high Sjögren's syndrome patients in the Dahlias Phase 2 trial. The safety profile remained consistent with prior studies, with no new safety signals identified. Johnson & Johnson is currently recruiting for a Phase 3 study.</p><p>Additionally, late-stage data for Tecvayli showed statistically significant improvements in progression-free and overall survival in advanced multiple myeloma, with nearly two-thirds of patients achieving complete response or better. The FDA also approved a label expansion for Tremfya covering structural joint damage progression in psoriatic arthritis.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"","article_id":"1160653703","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160653703","pubTimestamp":1780684784,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 6, Johnson & Johnson rose 3.02% in regular trading, trading at $235.1/share, with trading volume of $921 million. The rally was driven by a concentrated wave of positive clinical data...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生"},"translate_title":"动向预警|强生常规交易涨3.02%多项积极临床数据提振市场信心","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1},"content_text":"On June 6, Johnson & Johnson rose 3.02% in regular trading, trading at $235.1/share, with trading volume of $921 million. The rally was driven by a concentrated wave of positive clinical data disclosures across multiple pipeline programs.Specifically, Nipocalimab met its primary endpoint in a Phase 2 study of moderate-to-severe systemic lupus erythematosus, significantly reducing disease activity at 24 weeks as measured by the SLE Responder Index 4. The drug also demonstrated a 62.5% response rate in autoantibody-high Sjögren's syndrome patients in the Dahlias Phase 2 trial. The safety profile remained consistent with prior studies, with no new safety signals identified. Johnson & Johnson is currently recruiting for a Phase 3 study.Additionally, late-stage data for Tecvayli showed statistically significant improvements in progression-free and overall survival in advanced multiple myeloma, with nearly two-thirds of patients achieving complete response or better. The FDA also approved a label expansion for Tremfya covering structural joint damage progression in psoriatic arthritis.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160653703","isCrawlerRequest":true}